Document is current
Any future updates will be listed below
-
Authors
Desai, Nihar R.
Inzucchi, Silvio E.
Wright, Eugene E. Jr.
-
Funding
Funding for this research was provided by:
Boehringer Ingelheim
Eli Lilly and Company
- License Information
-
More Information
Article History
Received: 11 July 2025
Accepted: 23 February 2026
First Online: 15 April 2026
Declarations
:
: Nihar R. Desai: reports research grants and consulting for Amgen, AstraZeneca, Bayer, Boehringer Ingelheim, Bristol Myers Squibb, Cytokinetics, Merck, Novartis, scPharmaceuticals, and Vifor. Silvio E. Inzucchi: has served as a consultant or on clinical trial committees or advisory boards for AstraZeneca, Bayer, Boehringer Ingelheim, Corcept, Merck, Novo Nordisk, and Pfizer, and has delivered lectures sponsored by AstraZeneca and Boehringer Ingelheim. Eugene E. Wright Jr: has participated in speaker bureaus for Abbott Diabetes Care, Bayer, Boehringer Ingelheim, Eli Lilly, and Sanofi. He has served as a consultant/advisory board member for: Abbott Diabetes Care, Bayer, Boehringer Ingelheim, Eli Lilly, Embecta, Medtronic, and Sanofi. He also reports honorarium and writing support from Springer Health; advisor for Ascensia; content reviewer for UpToDate; and Clinical Diabetes Associate Editor for American Diabetes Association Publications.
: This article is based on previously conducted studies and does not contain any new studies with human participants or animals performed by any of the authors.
